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ABSTRACT  
Background: The transforming growth factor (TGF)-β and vascular endothelial growth factor 
(VEGF) pathways have been attributed a major role in the pathogenesis in glioblastoma, 
notably immunosuppression, migration and angiogenesis, but their interactions have remained 
poorly understood. 
Methods: We characterized TGF-β pathway activity in nine long-term glioma cell lines (LTC) 
and 4 glioma-initiating cell lines (GIC) in relation to constitutive and exogenous TGF-β-
induced VEGF release. Results were validated using TCGA transcriptomics data. 
Results: Glioma cells exhibit heterogeneous patterns of constitutive TGF-β  pathway 
activation reflected by phosphorylation not only of SMAD2 and SMAD3, but also 
SMAD1/5/8. Constitutive TGF-β pathway activity depends on the type I TGF-β receptor, 
ALK-5, and accounts for up to 69% of constitutive VEGF release which is positively 
regulated by SMAD2/3 and negatively by SMAD1/5/8 signaling in a cell line-specific 
manner. Exogenous TGF-β induces VEGF release in most cell lines, in a SMAD- and ALK-5-
dependent manner. There is no correlation between the fold induction of VEGF secretion 
induced by TGF-β compared to hypoxia. The role of SMAD5 signaling is highly context- and 
cell line dependent with a VEGF inhibitory effect at low TGF-β and pSMAD2 levels, and a 
stimulatory effect when TGF-β is abundant. 
Conclusions: TGF-β regulates VEGF release by glioma cells in an ALK-5-dependent manner 
involving SMAD2, SMAD3 and SMAD1/5/8 signaling. This crosstalk between the TGF-β 
and VEGF pathways may open up new avenues of biomarker-driven exploratory clinical trials 
focusing on the microenvironment in glioblastoma. 
Keywords: VEGF, TGF-β, glioblastoma, angiogenesis   
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INTRODUCTION 
Transforming growth factor (TGF)-β, a cytokine with pleiotropic functions, plays a pivotal 
role in cancer biology and represents one of the key pathogenic factors in glioblastoma. 
Ligand binding leads to the phosphorylation of SMAD family proteins which are involved in 
the regulation of gene transcription. Activation of the TGF-β / SMAD pathway correlates with 
poor prognosis in glioma patients1. Various anti-TGF-β strategies have been explored in 
rodent glioma models2-5 and clinical trials6,7. 
TGF-β signaling is mediated via a heterodimeric receptor complex comprising type I and type 
II receptors8. Canonical TGF-β signaling involves ligand binding to TGF-β receptor II (TGF-
βRII) which associates with the type I receptor activin receptor-like kinase-5 (ALK-5), 
resulting in the phosphorylation of SMAD2 and SMAD39. Pharmacological ALK-5 inhibition 
is an effective treatment strategy in rodent glioma models4,5,10. The involvement of another 
type I receptor in TGF-β signaling, the activin receptor-like kinase 1 (ALK-1), leading to the 
phosphorylation of SMAD1/5/8, has been characterized in endothelial cells11. This alternative 
pathway may counteract the ALK-5/pSMAD2 pathway and thereby balance TGF-β signaling.  
A role for TGF-β in modulating vascular endothelial growth factor (VEGF) release has been 
proposed in several cell types. Both negative and positive regulation of VEGF by TGF-β has 
been described in endothelial cells12,13. In glioma cells, the effect of TGF-β on the regulation 
of VEGF release remains uncertain, too. For selected glioma cell lines, a time-dependent 
increase of VEGF release induced by exogenous TGF-β has been reported14. Silencing of 
TGF-β1/2 or exposure to the ALK-5 inhibitor, SD-208, led to a reduced VEGF levels in the 
supernatant of LN-308 and LNT-229 glioma cells, indicating a role for TGF-β1/2 in the 
regulation of constitutive VEGF release in vitro15. However, pharmacological inhibition of 
ALK-5 by SB431542 inhibited the TGF-β-evoked VEGF release, but had only minor effects 
on constitutive VEGF release in D270MG or D423MG cells16. These observations raise the 
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possibility that VEGF is not only regulated via pSMAD2/3 signaling, but also involves other 
pathways in glioma cells.  
 
MATERIALS AND METHODS 
Cell culture 
Nine long-term malignant glioma cell lines (LTC)17, 4 glioma-initiating cell (GIC) lines18,19 
and hCMEC/D320 (supplementary material) were incubated under normoxia or in a hypoxia 
incubator (1% O2, 5% CO2, 37°C). 
Reagents 
Recombinant TGF-β2 (R&D, Minneapolis, MN) was used for all stimulation studies. SD-208 
(Scios Inc., Fremont, CA) inhibits ALK-5 at 0.048 µM in cell-free systems4. 
Immunoblot analyses 
Whole cell lysates were subjected to SDS-PAGE under reducing conditions loading equal 
amounts of proteins (supplementary material). SiRNA-mediated knockdown was applied to 
identify the specific band. For quantitative correlation analyses of baseline expression of total 
and phosphorylated SMAD proteins, band intensity was analyzed via densitometry using 
ImageJ software (Open Source). To compare the relative induction of phosphorylation after 
stimulation, we scored the response into no (<20%), low (20%-50%), medium (>50%) or high 
induction of phosphorylation (>100% or no baseline phosphorylation). 
Real-time PCR (RT-PCR) 
Gene expression was determined via real-time PCR (RT-PCR, procedure and primer 
sequences see supplement) using glycerinaldehyde-3-phosphate dehydrogenase (GAPDH) as 
a housekeeping gene with the ΔCTT-method for relative quantification. 
RNA interference 
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To silence gene expression, cells were transiently transfected using Metafectene® Pro 
(Biontex, Martinsried, Germany) for LTC and electroporation for GIC (Neon transfection 
system, Invitrogen, Basel, Switzerland) and siRNA pools (80-120 nM final concentration), 
containing four selected siRNA duplexes, each with a modification pattern addressing off-
target effects caused by both strands (ON-TARGETplus, SMARTpool, ON-TARGETplus 
Non-Targeting Pool siRNA as a negative control (Dharmacon, Lafayette, CO, SA). 
Flow cytometry 
Signal intensity of flow cytometry analysis (supplementary material) was calculated as the 
ratio of mean fluorescence of specific versus isotype control antibody (specific fluorescence 
index, SFI). 
Enzyme-linked immunosorbent assay (ELISA) 
Supernatants (preparation as outlined in the supplement) were analyzed by ELISA for VEGF 
levels (ebioscience, Vienna, Austria) and TGF-β1/2 (R&D).  
Luciferase reporter assay 
The pGL3 SBE-4-Luc plasmid (B. Vogelstein, Baltimore, MD) containing four copies of the 
Smad-binding element (SBE) GTCTAGAC21 was used for reporter gene assays 
(supplementary material). 
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RESULTS 
TGF-β  pathway activity in human glioma cells 
We first analyzed the expression levels of TGF-β receptors, their ligands, constitutive levels 
of total SMAD2-5, of phosphorylated SMAD2, SMAD3, and SMAD1/5/8, and the TGF-β  
target gene plasminogen activator inhibitor (PAI)-1. Correlation analyses of these parameters 
were performed either for all cell lines pooled or separately for LTC (Table 1). A separate 
analysis for the GIC was omitted because of small sample size. We validated our results using 
Affymetrix gene expression data from the TCGA (Supplementary Table 1). 
TGF-βRII, ALK-5 and ALK-1 mRNA were differentially expressed with a trend towards 
lower mRNA expression for all receptors in GIC. ALK-1 mRNA levels were lower than 
ALK-5 levels and more than 100-fold lower in glioma than in endothelial cells (Fig. 1A-C, 
left). The highest TGF-βRII protein levels were found for T98G cells while two of four GIC 
(T-269, S-24) had TGF-βRII levels at the detection limit. The SFI varied strongly for ALK-5 
from 84 in LN-18 cells to 1.7 in LN-308 cells. ALK-1 protein was not detected at the cell 
surface in glioma cells, using hCMEC as a positive control (Fig. 1A-C, right). Overall, mRNA 
levels were not predictive of protein levels. TGF-β1 and TGF-β2 were heterogeneously 
expressed on mRNA and protein level (Fig. 1D,E). TGF-β1 mRNA correlated with secreted 
TGF-β1, but not with TGF-β2 mRNA or protein. TGF-β2 mRNA correlated with TGF-βRII 
mRNA in our as well as TCGA database (Table 1, supplementary Table 1). 
pSMAD2 levels were highest in LN-428, LN-319, A172, LN-308, less in LN-18, D247 and 
T98G cells, below detection limit in the other cell lines, and correlated with pSMAD3 levels. 
pSMAD1/5/8 was low in 2 of 4 GIC (Fig. 1F). TGF-βRII and ALK-5 mRNA correlated with 
pSMAD2, and TGF-βRII surface expression with pSMAD1/5/8 levels. Phosphorylation of 
SMAD proteins as the proximate readout of TGF-β activity correlated with ligand expression 
as follows: pSMAD2 with TGF-β1 and TGF-β2 mRNA, pSMAD3 and pSMAD1/5/8 with 
TGF-β2 protein and inversely SMAD5 protein with the sum of TGF-β1 and TGF-β2 protein. 
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PAI-1 mRNA levels did not correlate with TGF-β receptors, ligands (mRNA or protein) or 
downstream phosphorylation of SMAD (Fig. 1G, Table 1).  
 
Endogenous TGF-β promotes VEGF expression and release in a cell line-specific manner 
VEGF expression on mRNA or protein level was similar in LTC and GIC (Fig. 2A,B). TGF-
β1 mRNA correlated with VEGF mRNA while total SMAD2 and total SMAD5 protein were 
inversely correlated with VEGF release. TGF-β1 and TGF-β2 mRNA correlated with VEGF 
mRNA and inversely also with SMAD2 mRNA in the TCGA database. However, neither 
TGF-β  receptor mRNA nor protein in our cell line panel nor of gene expression data of the 
TCGA nor pSMAD2/pSMAD3 nor pSMAD1/5/8 levels correlated with VEGF mRNA. PAI-1 
mRNA correlated with VEGF mRNA in the TCGA, but not in our dataset (Table 1, 
supplementary Table 1). 
We chose LN-308 cells because of their high endogenous TGF-β expression and high 
constitutive SMAD2 and SMAD3 phosphorylation to study the regulation of constitutive 
VEGF release. We added selected analyses for U87MG and ZH-161 cells. In LN-308, TGF-
βRII silencing, with an efficacy of 88% reduction assessed by RT-PCR (data not shown), 
reduced pSMAD2 and pSMAD3 levels, confirming the involvement of TGF-β and TGF-βRII 
in their constitutive regulation. Interestingly, pSMAD1/5/8 levels, too, were reduced upon 
silencing of TGF-βRII. Pharmacological inhibition of the kinase activity of ALK-5 by the 
small molecule inhibitor, SD-208 or silencing of ALK-5, led to reduced pSMAD2 and 
pSMAD3 levels, too, but did not affect constitutive pSMAD1/5/8 levels (Fig. 2C). To 
investigate the contribution of the different SMAD signaling pathways to constitutive VEGF 
release, we established gene silencing of SMAD2, SMAD3, SMAD2/3 in combination, or 
SMAD5 which led to specific reductions of the corresponding target proteins. As expected, 
pSMAD2, pSMAD3 and pSMAD1/5/8 were also reduced upon silencing of the respective 
SMAD proteins. In addition, silencing of SMAD proteins did not only affect their own 
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phosphorylation; instead, we observed reduced pSMAD3 upon silencing of SMAD2 in 
contrast to increased pSMAD2 upon silencing of SMAD3. pSMAD3 was increased upon 
silencing of SMAD5 while pSMAD2 was unaffected (Fig. 2D). 
Silencing of TGF-βRII reduced VEGF release in LN-308 cells (Fig. 2E). Inhibition of ALK-5 
by RNA interference or SD-208 reduced VEGF release in U87MG and LN-308 cells, too, 
although the reduction was not significant in ZH-161 (Fig. 2F). SMAD silencing had 
differential effects on VEGF release: SMAD2 or SMAD3 gene silencing reduced constitutive 
VEGF levels in U87MG and LN-308, but not ZH-161 (Fig. 2G). Even co-silencing of 
SMAD2 and SMAD3 failed to affect VEGF release in ZH-161, but further reduced VEGF 
levels in LN-308 exceeding the effect of silencing SMAD2 or SMAD3 alone. In contrast, 
silencing of SMAD5 increased the levels of constitutive VEGF release in U87MG cells, but 
had no effects in LN-308 or ZH-161 (Fig. 2H). 
 
Exogenous TGF-β promotes VEGF release in human malignant glioma cells 
We next assessed glioma cell responsiveness to exogenous TGF-β. All cell lines showed 
increased pSMAD2 and - except for S-24 - also pSMAD3, albeit to a differential extent. 
Relative pSMAD2 induction correlated inversely with the endogenous pSMAD2 (r=-0.66, 
p=0.01). pSMAD1/5/8 was increased in LN-319, A172 and U87MG LTC and T-325, ZH-
161, S-24 GIC (Fig. 3A). We next monitored the increase of TGF-β-dependent transcriptional 
activity using a SMAD-binding element (SBE) reporter plasmid21. TGF-β induced SBE 
reporter activity in all cell lines except in LN-428, A172, T-269 and S-24 cells. The highest 
response was observed in U87MG (26-fold) (Fig. 3B). Sufficient TGF-βRII surface 
expression was necessary for the induction of SBE reporter activity, given the poor response 
in T-269 and S-24 cells which exhibit TGF-βRII levels at the detection limit (Fig. 1A). In 
addition, high responsiveness correlated with pSMAD3 induction by TGF-β (r=0.62, p=0.02). 
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Surprisingly, the reporter-non-responsive cell lines LN-428 and A172 expressed high levels 
of ALK-5, in contrast to the highly responsive cell line U87MG (Fig. 1B). 
VEGF levels increased after TGF-β treatment in all cell lines except LN-428, A172 and S-24. 
The most pronounced increase was seen in U87MG cells (9-fold) (Fig. 3C). The response in 
U87MG was maintained but reduced in extent when these cells were switched to GIC culture 
conditions. In ZH-161, the response was further increased when switched to serum-containing 
medium for 2 passages. Under GIC conditions, basal VEGF synthesis was increased in 
U87MG both on mRNA and protein level and in ZH-161 on protein level (Supplementary 
Figure 1). Cell lines not exhibiting TGF-β2-dependent VEGF induction showed only minor 
induction of pSMAD2 and pSMAD3 by TGF-β2 (Fig. 3A). The induction of VEGF by TGF-β 
correlated with the induction of pSMAD3 (r=0.59, p=0.04) and reporter responsiveness 
(r=0.71, p=0.006). To assess whether cell lines not increasing VEGF release in response to 
TGF-β were generally less responsive to transcriptional activation of the VEGF gene, we 
exposed the same cell lines to hypoxia (1% O2, 24 h) as a major driver of VEGF gene 
transcription22. Hypoxia led to increased VEGF levels in almost all cell lines including LN-
428, A-172 and S-24 which did not increase VEGF release upon stimulation with TGF-β. 
Conversely, LNT-229 cells were unaffected, and D247MG showed even reduced VEGF 
release under hypoxia (Fig. 3D). Of note, hypoxia-induced VEGF release was overall higher 
in GIC, ranging from 1.9-fold (ZH-161) to 32-fold (T-269) than in LTC, ranging from 1.3-
fold (LN-18) to 2.1-fold (U87MG). Accordingly, we found only a minor induction of HIF-1α 
protein by hypoxia in LNT-229 which increased VEGF release in response to TGF-β, but not 
to hypoxia. Indeed, under normoxic conditions, we detected higher HIF-1α protein levels in 
ZH-161 than in LNT-229 cells. Of note, treatment with TGF-β left HIF-1α protein unaffected 
and there was no correlation between the magnitude of the VEGF response to TGF-β versus 
hypoxia (data not shown). We selected U87MG and ZH-161 cells to examine the time and 
concentration dependence of VEGF induction by TGF-β. On mRNA level, the highest 
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increase of VEGF (14-fold for U87MG and 1.4-fold for ZH-161) was observed at 4 h for 
U87MG and at 24-48 h for ZH-161 h (Fig. 3E). The induction of VEGF release into the 
supernatant was with 9-fold highest at 24 h for U87MG and 2-fold at 24-48 h in ZH-161 cells 
(Fig. 3F). Further, the induction of VEGF was concentration-dependent in U87MG and ZH-
161 cells on mRNA (Fig. 3G) and protein level (Fig. 3H). 
 
Molecular pathways mediating TGF-β–evoked VEGF release in glioma cells 
To explore the pathways mediating the stimulatory effect of exogenous TGF-β on VEGF 
release, we combined the inhibition of ALK-5 by SD-208 or siRNA, or siRNA-mediated gene 
silencing of SMAD2, SMAD3 or SMAD5, with the addition of exogenous TGF-β2. As 
expected, inhibition of ALK-5 by SD-208 or RNA interference reduced TGF-β2-evoked 
SMAD2 and SMAD3 phosphorylation in U87MG and ZH-161 cells. Interestingly, the 
induction of SMAD1/5/8 phosphorylation was abrogated by inhibition or silencing of ALK-5, 
too, suggesting a hitherto unrecognized TGF-β-dependent signal transduction pathway from 
ALK-5 to SMAD1/5/8 in glioma cells. Both pharmacological inhibition and silencing of 
ALK-5 interfered with the TGF-β2-mediated increase of VEGF (Fig. 4A, right panel). 
Silencing of SMAD2, SMAD3 or SMAD5 in U87MG or ZH-161 cells led to specific 
reductions of the target protein and reduced pSMAD2, pSMAD3 and pSMAD1/5/8 levels, 
respectively (Fig. 4B). Interestingly, TGF-β2-induced SMAD1/5/8 phosphorylation was 
further increased in case of SMAD2 or SMAD3 gene silencing in U87MG, but not in ZH-161, 
consistent with substrate competition of SMAD proteins for ALK-5 (Fig. 4B). TGF-β2-
evoked transcriptional activity was reduced upon silencing of either SMAD2, SMAD3 or 
SMAD5 in U87MG. A similar trend was observed in ZH-161, however, the reduction was 
only significant upon silencing of SMAD3 alone or combined with SMAD2 (Fig. 4C). In both 
cell lines, the TGF-β2-evoked VEGF release was reduced upon silencing of SMAD2 or 
SMAD3. Co-silencing of SMAD2 and SMAD3 had no superior effect over single silencing in 
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ZH-161. Further, silencing of SMAD5 reduced TGF-β2-evoked VEGF release in U87MG 
while the reduction was not significant in ZH-161 cells (Fig. 4D). 
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DISCUSSION 
 
Targeting angiogenesis is one of the major current strategies of glioblastoma treatment, but 
enthusiasm for this approach has declined after the failure of several anti-angiogenic agents in 
phase III trials23-25. Although the anti-VEGF antibody bevacizumab showed activity in 
recurrent glioblastoma in phase II trials26,27, no survival gain was achieved in two phase III 
trials in newly diagnosed glioblastoma28,29. Further, various attempts to improve anti-
angiogenic therapy by combination with cytotoxics were unsuccessful30. Nevertheless, VEGF 
is still one of the most promising targets to interfere with the malignant phenotype of 
glioblastoma. While hypoxia is considered the key driver of VEGF release in glioblastoma, 
hypoxia-independent control of VEGF release has received little attention. 
TGF-β, an important molecule shaping the microenvironment in glioblastoma, was 
characterized here as a positive regulator of the VEGF pathway. We provide a comprehensive 
analysis of the TGF-β pathway and its control of VEGF release in LTC and GIC models. 
Specifically, we analyzed the role of endogenous TGF-β as a model of autocrine signaling 
versus that of exogenous TGF-β, mimicking paracrine signals from the microenvironment. As 
a precondition for autocrine signaling, TGF-βRII and ALK-5 were widely expressed whereas 
ALK-1 was not (Fig. 1), indicating that an ALK-1/pSMAD1/5/8 signaling axis of VEGF 
release characterized in endothelial cells12 is not operating in glioma cells. All LTC released 
TGF-β1 and TGF-β2, while TGF-β2 was not detected in 2 of 4 GIC, confirming that 
therapeutic approaches targeting only one TGF-β  isoform are insufficient. Most cell lines 
exhibited phosphorylated SMAD2, SMAD3 or SMAD5, suggesting constitutive TGF-β 
pathway activation, confirmed by reduced pSMAD levels when TGF-βRII or ALK-5 
expression were suppressed, or ALK-5 inhibited pharmacologically (Fig. 2C). In non-
endothelial cells, BMP are considered as major drivers of SMAD1/5/8 phosphorylation, 
however, recently TGF-β-dependent phosphorylation of SMAD1/5/8 has been described, 
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although not yet for glioma cells31,32. We found that pSMAD1/5/8 levels in cellular lysates 
correlate with TGF-βRII levels at the surface and that TGF-βRII gene silencing reduced 
pSMAD1/5/8 levels (Fig. 2C). That inhibition of ALK-5 via SD-208 or ALK-5 gene silencing 
left pSMAD1/5/8 unaffected, suggests that a type-I receptor other than ALK-5 mediates 
SMAD1/5/8 phosphorylation in response to TGF-β. Still, we cannot rule out that these effects 
are mediated via minor ALK-1 levels escaping detection on protein level. 
To study the effect of endogenous TGF-β signaling on constitutive VEGF release, we 
interfered with different components of the TGF-β pathway. TGF-βRII gene silencing 
reduced VEGF release in LN-308 cells, confirming a role for TGF-β in the regulation of 
VEGF release in this cell line which releases high levels of active TGF-β33,34 (Fig. 2E). 
Furthermore, VEGF release required ALK-5 activity in LN-308 and U87MG cells, although 
not ZH-161 cells (Fig. 2F). This might suggest a robust TGF-β-independent VEGF secretion 
in GIC potentially due to constitutive HIF expression at normoxic conditions35 which we 
confirmed for ZH-161. SMAD2 and SMAD3 are necessary for TGF-β-dependent regulation 
of VEGF in LN-308 and U87MG cells, but again ZH-161 was unaffected even by combined 
SMAD2/3 silencing which was most effective in reducing VEGF in LN-308 cells (Fig. 2G). 
The role of SMAD5 in the regulation of constitutive VEGF release is more complex. LN-308 
and ZH-161 did not show major changes upon SMAD5 gene silencing whereas U87MG 
showed increased VEGF secretion (Fig. 2H). This can be explained by an indirect effect: 
BMP-2 being expressed by U87MG36 destabilizes HIF-1α in glioma cells37. Thus, depletion 
of SMAD5 resulting in reduced BMP signaling might increase the stability of HIF-1α, 
promoting VEGF release. Further, in endothelial cells a direct inhibitory effect of BMP-9 on 
VEGF via ALK-1/pSMAD1/5/8 signaling has been described38. Thus, TGF-β contributes to 
constitutive VEGF release in glioma cells via a TGF-βRII/ALK-5/SMAD2/3 signaling 
pathway. The pSMAD1/5/8 signaling axis driven by both TGF-β and BMP might be 
indirectly involved in selected cell lines, possibly as a negative feedback mechanism. 
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TGF-β is secreted not only by glioma cells but also by the tumor microenvironment, eg, 
endothelial, immune or microglial cells. Thus, we studied the effect of exogenous TGF-β on 
VEGF release. We observed a differential pattern of responsiveness to TGF-β as determined 
by changes in SMAD phosphorylation and reporter activity (Fig. 3A,B). We found that 
SMAD1/5/8 is also phosphorylated via TGF-β and ALK-5 in some glioma cell lines and may 
contribute to enhanced VEGF release (Fig. 3A, 4A,D). Sufficient TGF-βRII cell surface 
expression and phosphorylation of SMAD2/3 are necessary, but not sufficient, for SBE 
activation (Fig. 3B) and VEGF release (Fig. 3C), suggesting the involvement of additional 
downstream effectors. That high constitutive levels of pSMAD2 negatively correlated with 
the inducibility of pSMAD2 by exogenous TGF-β, suggests a saturation of the signaling 
pathway by autocrine TGF-β, leading to a decreased sensitivity towards exogenous TGF-β. 
ALK-5 expression was not predictive for sensitivity to exogenous TGF-β since cell lines with 
poor activation of the SBE reporter expressed rather high levels of ALK-5, and vice versa. 
Probably, post-transcriptional processes, e.g., involving deubiquitinating enzymes regulating 
TGF-β receptor stability39 modulate sensitivity towards TGF-β. 
Exogenous TGF-β induced VEGF release in most cell lines (Fig. 3C). Cells unresponsive to 
TGF-β did were still responsive to hypoxia with regard to VEGF induction, placing 
differential regulation upstream of the VEGF promotor (Fig. 3D). TGF-β-dependent SMAD3 
phosphorylation as well as transcriptional SBE activation correlated with TGF-β-evoked 
VEGF release, although no such correlation was seen for pSMAD2 or the TGF-β target gene, 
PAI-1. A differential activation of the transcription factor Sp1, a major driver of VEGF gene 
expression in non-hypoxic conditions40, via competing SMAD signaling pathways might play 
a role in this context. Of note, the VEGF promotor itself contains SBE sites and promotor 
activity is increased by SMADs41. That depletion of SMAD5 led to increased constitutive 
VEGF release (Fig. 2H), but reduced TGF-β-evoked VEGF release (Fig. 4D) in U87MG cells 
might be explained best via the dual activation of pSMAD1/5/8 by TGF-β and BMP. While 
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endogenous BMP signaling might inhibit constitutive VEGF expression either indirectly via 
destabilization of HIF37 or directly via BMP-9-ALK1 signaling as described for endothelial 
cells38, a relative predominance of TGF-β signaling might occur in the pharmacological 
context of exogenous stimulation by TGF-β inducing VEGF both via pSMAD2/3 and 
pSMAD1/5/8 signaling (Fig. 5).  
In summary, we show that TGF-β regulation of VEGF release in glioma cells depends, in an 
ALK-5-dependent manner, not only on SMAD2/3-dependent pathways, but also 
pSMAD1/5/8 signaling, suggesting that anti-TGF-β strategies may indirectly inhibit VEGF 
pathway activation in glioblastoma and this mechanism accounts for some of the angiogenic 
activity attributed to TGF-β. Moreover, since we have recently illustrated how integrin 
inhibition down-regulates TGF-β pathway activation in glioblastoma42, combinatorial 
therapeutic approaches targeting sequentially or in parallel integrins, TGF-β and VEGF based 
on preferential pathway activation may allow for better treatment options for glioblastoma. 
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Figure legends 
 
Figure 1. TGF-β receptor expression and TGF-β pathway activity in human glioma cells. 
A-C. Expression levels of TGF-β-RII (A), ALK-5 (B) and ALK-1 (C) on mRNA level 
assessed by RT-PCR (left) and protein level (SFI) assessed by flow cytometry (middle) (A,B). 
Representative flow cytometry profiles are shown on the right. Data are expressed as mean 
and SEM of 2-4 independent experiments. D. Expression of TGF-β1 (squares) and TGF-β2 
(circles) mRNA assessed by RT-PCR. E. LTC were serum-starved for 24 h and then exposed 
to serum-free medium for 24 h, GIC were seeded, 24 h later changed to fresh medium, and 
supernatants harvested 24 h thereafter. TGF-β1 (open bars) or TGF-β2 (striped bars) released 
into the supernatant were analyzed by ELISA (mean and SEM, n=2, in duplicates, “n.d.” 
below detection limit). F. Whole cell lysates of LTC (24 h serum-starved) or GIC were 
subjected to immunoblotting. Representative loading controls for GAPDH or β-actin are 
included. G. PAI-1 mRNA expression assessed by RT-PCR. 
 
Figure 2. Control of VEGF release by constitutive TGF-β pathway activity. A. VEGF 
mRNA (A) analyzed by RT-PCR and VEGF release into the supernatant (B) prepared as in 
Fig. 1D and analyzed by ELISA (mean and SEM, n=5 in duplicates or triplicates) in LTC and 
GIC. C. Representative immunoblots (SMAD2, pSMAD2, SMAD3, pSMAD3, SMAD5, 
pSMAD1/5/8, GAPDH) of LN-308 cells after transfection with siRNA targeting TGF-βRII 
(72 h) or ALK-5 (48 h) or after pharmacologicial inhibition of ALK-5 by SD-208 (1 µM, 24 
h) or respective controls (non-targeting siRNA or DMSO). D. Representative immunoblots of 
LN-308 cells with siRNA targeting SMAD2 (48 h), SMAD3 (48 h), SMAD2 and SMAD3 
(48h) or SMAD5 (72 h) or non-targeting control. E. Supernatants of LN-308 cells harvested 
72 h after transfection with siRNA targeting TGF-βRII were assessed for VEGF levels by 
ELISA. F. Supernatants of U87MG, LN-308 and ZH-161 cells were analyzed for VEGF by 
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ELISA after exposure to ALK-5 siRNA (left, 48 h post transfection for LN-308 and ZH-161, 
72 h for U87MG) or SD-208 (right, 24 h, 1 µM). G, H. Supernatants harvested after 
transfection with siRNA targeting SMAD2 (24 h for U87MG and ZH-161, 48 h for LN-308), 
SMAD3 (36 h for U87MG, 48 h for LN-308, 24 h for ZH-161), SMAD2/3 (36 h for U87MG, 
48 h for LN-308, 24 h for ZH-161) (G) or SMAD5 (24 h for U87MG and ZH-161, 48 h for 
LN-308) (H). Shown are representative experiments performed in triplicates (student’s t-test, 
*p<0.05). 
 
Figure 3. Stimulation of VEGF release by exogenous TGF-β. A. TGF-β pathway 
inducibility was examined by assessing the induction of pSMAD2, pSMAD3 or pSMAD1/5/8 
via immunoblot with or without stimulation with TGF-β2 (10 ng/ml) for 24 h after 24 h serum 
starvation. Shown are immunoblots of SMAD2, pSMAD2, SMAD3, pSMAD3, SMAD5, 
pSMAD1/5/8, and representative loading controls for GAPDH and β-actin. B. Transcriptional 
activation by TGF-β was assessed by a SBE reporter assay. Shown are relative units (RU) of 
SBE reporter signal after stimulation with TGF-β2 (10 ng/ml) for 24 h normalized to 
untreated control. C,D. The supernatants of glioma cell lines maintained with or without 10 
ng/ml TGF-β2  for 24 h (C) or with or without hypoxia (D) after a 24 h period of serum 
starvation were analyzed for VEGF by ELISA. E,F. VEGF was assessed after 4, 24 and 48 h 
exposure to 10 ng/ml TGF-β2 in U87MG or ZH-161 on mRNA level (E) or protein level 
using cell culture supernatants as in A (F). G,H. U87MG or ZH-161 cells were analyzed for 
VEGF after 24 h stimulation with TGF-β2 at 0, 0.1, 1 or 10 ng/ml on mRNA level (G) and in 
cell culture supernatants (H). 
 
Figure 4. TGF-β-dependent increase of VEGF is mediated by ALK-5 and involves 
different SMAD signaling pathways. A. U87MG or ZH-161 cells were treated without or 
with SD-208 (1 µM, 25 h) or siRNA targeting ALK-5 (72 h for U87MG, 48 h for ZH161) and 
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24 h before harvesting with or without TGF-β2 (10 ng/ml). Total SMAD2, pSMAD2, 
SMAD3, pSMAD3, SMAD5, pSMAD1/5/8 or GAPDH were analyzed by immunoblot. 
Supernatants were analyzed for VEGF by ELISA. B. Levels of total SMAD2, pSMAD2, 
SMAD3, pSMAD3, SMAD5, pSMAD1/5/8 or GAPDH were assessed by immunoblot after 
silencing of SMAD2 (24 h), SMAD3 (36 h for U87MG, 24 h for ZH-161), SMAD2 and 
SMAD3 (ZH-161, 24 h) or SMAD5 (24h) without or with additional treatment with TGF-β2 
(10 ng/ml, 12-24 h). C. Effect of silencing of SMAD2, SMAD3 or SMAD5 or respective 
controls on transcriptional activation in U87MG or ZH-161 cells without or with treatment 
with TGF-β2 (10 ng/ml, 12 h) was examined by SBE reporter assay. Shown are RU of SBE 
reporter signal normalized to untreated control-transfected samples. D. Supernatants from 
cells treated as in B were assessed for VEGF by ELISA. 
 
Figure 5. TGF-β-dependent regulation of VEGF release in glioblastoma. Proposed model 
for the regulation of VEGF by TGF-β (straight arrows) and HIF (dotted arrows). TGF-β 
released from cells of the tumor microenvironment, e.g., endothelial, immune and microglial 
cells, signals via TGF-βRII and ALK-5 leading to phosphorylation of SMAD2, SMAD3 and 
SMAD1/5/8 and increased VEGF release. BMP-dependent pSMAD1/5/8 signaling (dashed 
arrows) destabilizes HIF and thereby indirectly reduces VEGF. TGF-β-dependent 
SMAD1/5/8 signaling requires, beyond TGF-βRII, a non-ALK-5-type-I-receptor (TGF-β-RI-
x). Overall, VEGF release is modulated in a cell-specific and context-dependent manner, with 
a predominance of either hypoxia-, TGF-β- or BMP-driven signaling: for ZH-161 GIC, 
exhibiting low endogenous TGF-β levels but stable endogenous HIF-1α, VEGF release is 
highly resistant to TGF-β pathway inhibition at baseline conditions, but sensitive when TGF-β 
is abundant. In contrast, LN-308 cells, characterized by high endogenous TGF-β and 
pSMAD2/3, are highly sensitive for TGF-β pathway inhibition via ALK-5 and SMAD2/3, but 
not for inhibition of SMAD5 at baseline. In U87MG cells, the duality of pSMAD1/5/8 
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signaling as driven both by TGF-β and BMPs becomes apparent: SMAD5 at baseline 
conditions with low endogenous TGF-β negatively regulates VEGF, probably via BMP-
driven destabilization of HIF, but positively regulates VEGF when TGF-β is abundant. 
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Supplementary Methods 
Cell culture 
The 9 long-term glioblastoma cell lines (LTC)17 were maintained in Dulbecco´s modified 
Eagle´s medium supplemented with 10% fetal calf serum (FCS) and last subjected to 
authentification tests at the German Biological Resource Centre DSMZ in Braunschweig, 
Germany, in November 2013. The 4 glioma-initiating cell (GIC) lines were established after 
informed consent and approval of the local ethics committees and characterized in our 
laboratories in Tübingen and Zurich18,19 as well as via comparative genomic hybridization by 
R. Weber (Department of Genetics, University of Hannover) and maintained in Neurobasal 
Medium supplemented with B-27 (20 μl/ml) and Glutamax (10 μl/ml) from Invitrogen (Basel, 
Switzerland), fibroblast growth factor (FGF)-2, epidermal growth factor (EGF) (20 ng/ml 
each; Peprotech, Rocky Hill, PA) and heparin (32 IE/ml; Ratiopharm, Ulm, Germany). 
hCMEC/D3, a human brain endothelial cell line previously characterized20, was maintained 
maintained in EndoPrime medium supplemented with Endoprime Supplement, EGF, VEGF 
and fetal bovine serum (FBS) (PAA laboratories, Pasching, Austria). We instituted a 24 h 
incubation in serum-free medium of 24 h for preparation of baseline analyses as well as 
before any treatment steps. Serum deprivation was applied to remove serum as a confounder 
for LTC. We verified that this switch of culture conditions did not affect TGF-β activity as 
assessed by pSmad2 levels (data not shown).  
Preparation of whole cell lysates and immunoblot analyses  
Whole cell lysates were prepared in lysis buffer containing 25 mM Tris-HCL, 120 mM NaCl, 
5 mM EDTA and 0.5% NP-40 supplemented with 2 µg/mL aprotinin, 10 µg/mL leupeptin 
and 100 µg/mL phenylmethylsulfonyl fluoride (Sigma Aldrich) and phosphatase inhibitor 
cocktails 2 and 3 (Sigma Aldrich). Protein levels were determined using a Bradford-based 
protein assay (Biorad, Munich, Germany). After SDS-PAGE, proteins were transferred to 
nitrocellulose membranes (Biorad, Munich, Germany), blocked in Tris-buffered saline 
containing 5% skim milk and 0.1% Tween 20 following antibody incubation. The following 
antibodies were used: anti-SMAD2 (3122S), anti-pSMAD2 (3108S), anti-SMAD3 (9513S), 
anti-pSMAD3 (9520S), anti-SMAD5 (9517S), anti-pSMAD1/5/8 (9511S) (all Cell Signaling, 
Boston, MA) anti-GAPDH (EB07069, Everest Biotech, Oxfordshire, UK), anti-β-actin (sc-
1616, santa cruz biotechnology, Santa Cruz, CA). Visualization of protein bands was 
accomplished using horseradish peroxidase (HRP)-coupled secondary antibodies (Santa cruz 
Biotechnology) and enhanced chemoluminescence (Pierce/Thermo Fisher, Madison, WI). 
Real-time PCR (RT-PCR) 
Total mRNA extraction was done using the NucleoSpin® RNA II (Macherey-Nagel, Düren, 
Germany) system including DNase treatment. cDNA was prepared using Superscript reverse 
transcriptase II (Invitrogen) and random primer 9 (New England BioLabs, Ipswich, MA) or 
the iScript™ cDNA synthesis kit (Biorad Laboratories, Reinach, Germany). For real-time 
PCR (RT-PCR), gene expression was measured using the Real Time PCR System 7300 
(Applied Biosystems, Foster City, CA) with SYBR Green Master Mix (AppliChem, 
Darmstadt, Germany) and primers at optimized concentrations. The conditions for RT-PCR 
were 40 cycles, 95°C/15s, 60°C, 1 min. Relative quantification of gene expression was 
determined by comparison of threshold values. The following primers were used: GAPDH 
(forward 5'-CTC TCT GCT CCT CCT GTT CGA C-3', reverse 5'-TGA GCG ATG TGG 
CTC GGC T-343), VEGF (forward 5'-GAG ACC CTG GTG GAC ATC TT-3', reverse 5'-
TTG ATC CGC ATA ATC TGC AT-3, Microsynth, Balgach, Switzerland), ALK-1 (Lot no. 
98730849, Qiagen, Hilden, Germany), ALK-5 (Lot no. 6734902_1855089_88442_88443, 
Qiagen), PAI-1 (forward 5´-CAGAAAGTGAAGATCGAGGTGAAC-3′, reverse 5´-
GGAAGGGTCTGTCCATGATGAT-3′ 44), TGF-β1 (forward 5′-
GCCCTGGACACCAACTATTG-3′, reverse 5′-CGTGTCCAGGCTCCAAATG-3′), TGF-β2, 
(forward 5′-AAGCTTACACTGTCCCTGCTGC-3′, reverse 5′-
TGTGGAGGTGCCATCAATACCT-3′ 45, Microsynth), TGF-βRII (Lot no. 98554236, 
Qiagen). 
 
Flow cytometry 
LTC were detached using Accutase (PAA Laboratories), GIC were mechanically dissociated 
and blocked with 0.5% bovine serum albumin (BSA) in phosphate-buffered saline (PBS). 
Selected experiments regarding ALK-1 detection in adherent cells were confirmed using 
mechanical dissociation of cells using a cell scraper to exclude receptor loss by accutase 
treatment. The cells were incubated for 30 min at 4°C using the following primary antibodies: 
anti-human TGF-βRI/ALK-5 (AF3025, R&D systems, Minneapolis, MN), anti-TGF-βRII 
(ab78419, abcam, Cambridge, UK), anti-human ALK-1 (PF-03446962, Pfizer, New York, 
NY) or appropriate isotype controls (normal goat IgG, sc-2028, Santa Cruz Biotechnology, 
Santa Cruz, CA), mouse IgG1 (557273, Becton Dickinson, Franklin Lakes, NJ), human IgG 
(Sigma Aldrich, Buchs, Switzerland). After 2 washing steps with PBS containing 0.5% BSA, 
cells were incubated at 4°C with the following secondary antibodies: anti-goat IgG-FITC 
(F2016, Sigma Aldrich), anti-mouse IgG1-PE (RMG1-1, Biolegend, London, UK), anti-
human Alexa Fluor 488 antibody (Invitrogen). Subsequently, the cells washed twice with PBS 
containing 0.5% BSA and subjected to flow cytometry analysis. A Cyan® Dako flow 
cytometer was used and data were analyzed via Summit® software version 4.3 (Beckmann 
Coulter, Krefeld, Germany). Signal intensity was calculated as the ratio of the mean 
fluorescence of the specific antibody and the isotype control antibody (specific fluorescence 
index, SFI). A SFI of 1.3 was arbitrarily defined as a significant surface expression. 
Enzyme-linked immunosorbent assay  
Cell supernatants from LTC were collected at subconfluency, seeded at 2.6 x 104 cells/cm2, 
and from GIC, seeded in suspensions of 0.6 x 106/ml, respectively, after the indicated time 
periods. For transfection experiments, LTC were seeded at higher densities between 6.6 and 
7.5 x 104 cells/cm2. For LTC a 24 h period of serum deprivation was included prior the 
indicated time periods. Cellular debris was removed by centrifugation. Results of ELISA were 
expressed normalized to the cell number seeded with 2.6 x 104 cells/cm2 (LTC) or 0.6 x 
106/ml (GIC). For experiments with previous transfection, an additional correction for overall 
protein concentration in the supernatant was done for LTC. Since the B27 supplement of the 
medium perturbs protein measurement in the supernatant, cell counts were obtained for GIC 
cultures before harvesting the supernatants and results were normalized to the cell count of 
control-transfected cells. 
Luciferase reporter assay 
Transcriptional activity was measured by a dual luciferase reporter gene assay. Cells were co-
transfected using Metafectene Pro transfection reagent (Biontex, Martinsried, Germany) for 
LTC and with electroporation (Neon transfection system, Invitrogen) for GIC with SBE-Luc 
plasmid21 and renilla reniformis-CMV (pRL-CMV) control plasmid (Promega, Madison, WI) 
at a ratio of 7.5:1. Firefly/renilla luciferase activities were determined sequentially and 
normalized to Renilla activity. Results were further normalized to untreated control cells as 
indicated. 
Database interrogations 
Correlation analyses of genes were downloaded from the R2 microarray analysis and 
visualization platform using normalized Affymetrix gene expression data in The Cancer 
Genome Atlas (TCGA)-540 database (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi#, available 
on 15 February 2014). 
Statistical analysis 
Data are commonly derived from experiments performed three times with similar results. If 
not otherwise indicated, results of representative experiments are shown. Statistical 
significance was assessed using two-sided unpaired Student’s t-test. Means, standard error of 
the mean (SEM) and correlation (r=Spearman’s coefficient) were calculated using the 
software of GraphPad Prism Version 5 (San Diego, CA). A p-value of p=0.05 was considered 
to be statistically significant.  

Supplementary Figure 1. The induction of VEGF by TGF-β  is independent of culture 
conditions  
U87MG or ZH-161 cells were passaged in parallel in their native culture conditions or after 2 
passages in GIC conditions (NB) for U87MG and LTC conditions (DM) for ZH-161. VEGF 
mRNA induction by TGF-β2 (10 ng/ml, 24 h) was assessed by RT-PCR (A) and protein 
release by ELISA (B, results adjusted to cell count performed after harvesting the 
supernatants).  
 
Supplementary Table 1: Correlation analyses of gene expression data in the Tumor Glioblastoma - TCGA - 540 database: 
Correlation analyses of genes were derived from normalized Affymetrix gene expression data in the TCGA - 540 database and downloaded from the 
R2 microarray analysis and visualization platform. The affymetrix code for the probeset is given in brackets. 
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